iX Biopharma Ltd. announced on Jul, 07 2026 that it has allotted and issued about 6.32 million new ordinary shares pursuant to the exercise of warrants at an exercise price of 0.06 Singapore dollars per share.

Following the issuance, the company’s total share capital increased from approximately 1.068 billion to 1.075 billion shares. The new shares rank pari passu with existing shares and are expected to begin trading on the Singapore Exchange on Jul, 09 2026.

The company said 38.35 million warrants—representing 66.69% of those originally issued—have now been exercised, leaving 19.16 million warrants outstanding, each exercisable at 0.06 Singapore dollars per share. The warrants will expire at 5:00 p.m. on Jul, 17 2026; the last day of trading is set for Jul, 10 2026, with trading cessation at 9:00 a.m. on Jul, 13 2026 and delisting scheduled for Jul, 20 2026.